台灣臨床試驗主持人資料庫|TPIDB

2017-10-01 - 2020-01-08

Phase II

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Condition/Disease

Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Test Drug

INCB039110

Participate Sites
2Sites

Terminated2Sites

2017-09-01 - 2023-04-20

Phase III

Condition/Disease
Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

王鵬惠

Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2015-10-01 - 2020-04-30

Phase III

SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor (AI) treatment

Condition/Disease

hormone receptor positive, HER2-negative advanced breast cancer
Test Drug

BYL719/Faslodex

Participate Sites
3Sites

Terminated3Sites

曾令民

Taipei Veterans General Hospital

2018-07-02 - 2021-06-08

Phase II

A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer

Condition/Disease

Advanced Triple-negative Breast Cancer
Test Drug

LAG525、PDR001

Participate Sites
3Sites

Terminated3Sites

曾令民

Taipei Veterans General Hospital

2017-08-28 - 2019-10-02

Phase III

Condition/Disease
Test Drug

Participate Sites
3Sites

Terminated3Sites

陳涵栩

Taipei Veterans General Hospital

Division of Endocrinology

2018-02-15 - 2019-07-16

Phase III

Condition/Disease
Test Drug

Participate Sites
1Sites

Terminated1Sites

常敏之

Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2017-01-01 - 2019-08-31

Phase I

A Phase I/IIa, Open label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy

Condition/Disease

Advanced Malignancy
Test Drug

LipoVNB Vinorelbine Tartrate

Participate Sites
2Sites

Terminated2Sites

顏厥全

Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-04-01 - 2019-09-30

Phase I

Phase 1, Multicenter, Open-label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2-Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer

Condition/Disease

Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer
Test Drug

DS-8201a

Participate Sites
2Sites

Terminated2Sites

趙毅

Taipei Veterans General Hospital

2016-08-31 - 2018-12-31

Phase III

A Randomized, Open-label, Japan-Korea-Taiwan Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy versus Irinotecan Monotherapy as Second Line Treatment in Subjects with Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

Condition/Disease

Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer
Test Drug

DE-766 injection 50 mg/10mL vial

Participate Sites
11Sites

Terminated10Sites

趙毅

Taipei Veterans General Hospital

2018-08-24 - 2021-01-29

Phase II

A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve physical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF)

Condition/Disease

正常收縮分率心臟衰竭(HFpEF)
Test Drug

Vericiguat, BAY 1021189

Participate Sites
4Sites

Terminated4Sites

江晨恩

Taipei Veterans General Hospital

Division of Cardiovascular Diseases

Search Result

List